RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A

Sponsor: Arditus Pte Ltd • ClinicalTrials.gov ID: NCT07787091

Registry updated: 2026-08-26

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study is evaluating ARD001, an investigational medicine being developed for the treatment of hemophilia A. In Phase 1, healthy adult participants will receive a single dose of ARD001 or placebo to assess its safety and tolerability, how it moves through the body, its effects on blood coagulation, and whether the body develops antibodies against it. If the Phase 1 results support further study and the required regulatory and ethics approvals are obtained, Phase 2 will evaluate repeated doses of ARD001 in adults with hemophilia A. Phase 2 is not currently open for enrollment. The study is designed to determine whether ARD001 can be administered with acceptable safety and to identify doses suitable for further clinical development.

Interventions

ARD001 (Biological)
ARD001 will be administered subcutaneously as a single dose of 0.01, 0.1, or 0.3 mg/kg in Phase 1. A multiple-dose regimen is planned for Phase 2 and will be specified in a protocol amendment before Phase 2 initiation
Placebo (Other)
The corresponding placebo will be administered subcutaneously as a single dose in Phase 1

Eligibility criteria

Phase 1 Inclusion Criteria: * Healthy adults within the specified age and body-weight ranges * Able and willing to provide informed consent * Considered healthy based on medical history, physical examination, vital signs, electrocardiogram and laboratory assessments * Other essential criteria from the approved protocol Phase 1 Exclusion Criteria: * History of severe drug or food allergy, or known allergy to ARD001 or its components * Acute infection within 14 days before dosing or fever on the planned dosing day * Clinically significant cardiovascular, coagulation, hepatic, renal or other medical abnormality * Recent use of prohibited medications within the protocol-defined washout periods * Other major exclusions from the approved protocol

Conditions

Hemophilia A Healthy Adult Participants

Locations

SingHealth Investigational Medicine Unit — Singapore, Singapore

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment